Drugs / ALXN2420
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07037420 | Oct 2025 → Jan 2027 expected | acromegaly | Alexion Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALXN2420 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07037420 ↗ |
| Route | Subcutaneous | “ALXN2420 will be administered via subcutaneous (SC) injection” NCT07037420 ↗ |